Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells

Gynecologic Oncology

Volumn 105, Issue 1, 2007, Pages 31-44

  Villedieu, M ^a   Louis, M H ^a   Dutoit, S ^a   Brotin, E ^a   Lincet, H ^a   Duigou, F ^a   Staedel, C ^a   Gauduchon, P ^a   Poulain, L ^a  

^a CLCC Centre de Lutte Contre le Cancer François Baclesse   (France)

Author keywords

Apoptosis; Bcl 2 family; Chemotherapy; Gene therapy

Indexed keywords

CISPLATIN; MESSENGER RNA; PROTEIN BCL XL; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; PROTEIN BCL X; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TRANSFER; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; BIOSYNTHESIS; CELL CYCLE; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; GENETIC TRANSFECTION; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION;

EID: 33947324515     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.12.011     Document Type: Article

References (75)

1. Awada A., and Klastersky J. Ovarian cancer: state of the art and future directions. Eur. J. Gynaecol. Oncol. 25 (2004) 673-676
2. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 351 (2004) 2519-2529
3. Ozols R.F. Treatment goals in ovarian cancer. Int. J. Gynecol. Cancer 15 Suppl. 1 (2005) 3-11
4. Parker R.J., Eastman A., Bostick-Bruton F., and Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. 87 (1991) 772-777
5. Andrews P.A., Velury S., Mann S.C., and Howell S.B. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 48 (1988) 68-73
6. Godwin A.K., Meister A., O'Dwyer P.J., Huang C.S., Hamilton T.C., and Anderson M.E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 3070-3074
7. Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., and Hamilton T.C. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res. 57 (1997) 850-856
8. Nyce J.W. Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat. Res. 386 (1997) 153-161
9. Hickman J.A., Beere H.M., Wood A.C., Waters C.M., and Parmar R. Mechanisms of cytotoxicity caused by antitumour drugs. Toxicol. Lett. (1992) 64-65 Spec. No:553-561
10. Fisher D.E. Apoptosis in cancer therapy: crossing the threshold. Cell 78 (1994) 539-542
11. Segal-Bendirdjian E., and Jacquemin-Sablon A. Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process. Exp. Cell Res. 218 (1995) 201-212
12. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
13. Wang D., and Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev., Drug Discov. 4 (2005) 307-320
14. Arts H.J., Van Der Zee A.G., De Jong S., and De Vries E.G. Options for modulation of drug resistance in ovarian cancer. Int. J. Gynecol. Cancer 10 (2000) 47-52
15. Robert J. Resistance to cytotoxic agents. Curr. Opin. Pharmacol. 1 (2001) 353-357
16. Yang X., Fraser M., Moll U.M., Basak A., and Tsang B.K. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res. 66 (2006) 3126-3136
17. Lee S., Choi E.J., Jin C., and Kim D.H. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol. Oncol. 97 (2005) 26-34
18. West K.A., Castillo S.S., and Dennis P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat. 5 (2002) 234-248
19. Mansouri A., Zhang Q., Ridgway L.D., Tian L., and Claret F.X. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol. Res. 13 (2003) 399-404
20. Cheng J.Q., Jiang X., Fraser M., Li M., Dan H.C., Sun M., et al. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist. Updat. 5 (2002) 131-146
21. Nunez G., and Clarke M.F. The Bcl-2 family of proteins: regulators of cell death and survival. Trends Cell Biol. 4 (1994) 399-403
22. White E. Life, death, and the pursuit of apoptosis. Genes Dev. 10 (1996) 1-15
23. Cory S., and Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev., Cancer 2 (2002) 647-656
24. Korsmeyer S.J. BCL-2 gene family and the regulation of programmed cell death. Cancer Res. 59 (1999) 1693s-1700s
25. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
26. Dejean L.M., Martinez-Caballero S., Manon S., and Kinnally K.W. Regulation of the mitochondrial apoptosis-induced channel, MAC, by BCL-2 family proteins. Biochim. Biophys. Acta 1762 (2006) 191-201
27. Kroemer G., Zamzami N., and Susin S.A. Mitochondrial control of apoptosis. Immunol. Today 18 (1997) 44-51
28. Kirkin V., Joos S., and Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta 1644 (2004) 229-249
29. Minn A.J., Rudin C.M., Boise L.H., and Thompson C.B. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86 (1995) 1903-1910
30. Dole M.G., Jasty R., Cooper M.J., Thompson C.B., Nunez G., and Castle V.P. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res. 55 (1995) 2576-2582
31. Simonian P.L., Grillot D.A., and Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 90 (1997) 1208-1216
32. Kyprianou N., King E.D., Bradbury D., and Rhee J.G. bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int. J. Cancer 70 (1997) 341-348
33. Luo D., Cheng S.C., Xie H., and Xie Y. Effects of Bcl-2 and Bcl-XL protein levels on chemoresistance of hepatoblastoma HepG2 cell line. Biochem. Cell. Biol. 78 (2000) 119-126
34. Lebedeva I., Rando R., Ojwang J., Cossum P., and Stein C.A. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res. 60 (2000) 6052-6060
35. Konopleva M., Zhao S., Hu W., Jiang S., Snell V., Weidner D., et al. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br. J. Haematol. 118 (2002) 521-534
36. Amundson S.A., Myers T.G., Scudiero D., Kitada S., Reed J.C., and Fornace Jr. A.J. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60 (2000) 6101-6110
37. Liu J.R., Fletcher B., Page C., Hu C., Nunez G., and Baker V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol. Oncol. 70 (1998) 398-403
38. Marone M., Scambia G., Mozzetti S., Ferrandina G., Iacovella S., De Pasqua A., et al. bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues. Clin. Cancer Res. 4 (1998) 517-524
39. Baekelandt M., Holm R., Nesland J.M., Trope C.G., and Kristensen G.B. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J. Clin. Oncol. 18 (2000) 3775-3781
40. Williams J., Lucas P.C., Griffith K.A., Choi M., Fogoros S., Hu Y.Y., et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol. Oncol. 96 (2005) 287-295
41. Kassim S.K., Ali H.S., Sallam M.M., Fayed S.T., Seada L.S., abd-Elkawy E., et al. Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer. Clin. Biochem. 32 (1999) 333-338
42. Dodier P., and Piche A. Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells. Gynecol. Oncol. 100 (2006) 254-263
43. Beale P.J., Rogers P., Boxall F., Sharp S.Y., and Kelland L.R. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br. J. Cancer 82 (2000) 436-440
44. Poulain L., Lincet H., Duigou F., Deslandes E., Sichel F., Gauduchon P., et al. Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. Int. J. Cancer 78 (1998) 454-463
45. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48 (1988) 4827-4833
46. Darzynkiewicz Z., Bruno S., Del Bino G., Gorczyca W., Hotz M.A., Lassota P., et al. Features of apoptotic cells measured by flow cytometry. Cytometry 13 (1992) 795-808
47. Ziller C., Lincet H., Muller C.D., Staedel C., Behr J.P., and Poulain L. The cyclin-dependent kinase inhibitor p21(cip1/waf1) enhances the cytotoxicity of ganciclovir in HSV-tk transfected ovarian carcinoma cells. Cancer Lett. 212 (2004) 43-52
48. Menegoz F., Black R.J., Arveux P., Magne V., Ferlay J., Buemi A., et al. Cancer incidence and mortality in France in 1975-95. Eur. J. Cancer Prev. 6 (1997) 442-466
49. Ozols R.F. Current status of chemotherapy for ovarian cancer. Semin. Oncol. 22 (1995) 61-66
50. Krajewska M., Fenoglio-Preiser C.M., Krajewski S., Song K., Macdonald J.S., Stemmerman G., et al. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am. J. Pathol. 149 (1996) 1449-1457
51. Maurer C.A., Friess H., Buhler S.S., Wahl B.R., Graber H., Zimmermann A., et al. Apoptosis inhibiting factor Bcl-xL might be the crucial member of the Bcl-2 gene family in colorectal cancer. Dig. Dis. Sci. 43 (1998) 2641-2648
52. Boise L.H., Gonzalez-Garcia M., Postema C.E., Ding L., Lindsten T., Turka L.A., et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74 (1993) 597-608
53. Gonzalez-Garcia M., Perez-Ballestero R., Ding L., Duan L., Boise L.H., Thompson C.B., et al. bcl-XL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. Development 120 (1994) 3033-3042
54. Krajewski S., Tanaka S., Takayama S., Schibler M.J., Fenton W., and Reed J.C. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 53 (1993) 4701-4714
55. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A., et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9 (1994) 1799-1805
56. Song H., Sondak V.K., Barber D.L., Reid T.J., and Lin J. Modulation of Janus kinase 2 by cisplatin in cancer cells. Int. J. Oncol. 24 (2004) 1017-1026
57. Qin L.F., and Ng I.O. Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Cancer Lett. 175 (2002) 27-38
58. Dutta T., Sharma H., Kumar L., Dinda A.K., Kumar S., Bhatla N., et al. Neoadjuvant chemotherapy for epithelial ovarian cancer-role of apoptosis. Cancer Chemother. Pharmacol. 56 (2005) 427-435
59. Mazel S., Burtrum D., and Petrie H.T. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J. Exp. Med. 183 (1996) 2219-2226
60. O'Reilly L.A., Huang D.C., and Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J. 15 (1996) 6979-6990
61. Vairo G., Innes K.M., and Adams J.M. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 13 (1996) 1511-1519
62. Brady H.J., Gil-Gomez G., Kirberg J., and Berns A.J. Bax alpha perturbs T cell development and affects cell cycle entry of T cells. EMBO J. 15 (1996) 6991-7001
63. Minn A.J., Boise L.H., and Thompson C.B. Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev. 10 (1996) 2621-2631
64. Milner B.J., Allan L.A., Eccles D.M., Kitchener H.C., Leonard R.C., Kelly K.F., et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res. 53 (1993) 2128-2132
65. Mitra R.S., Benedict M.A., Qian D., Foreman K.E., Ekhterae D., Nickoloff B.J., et al. Killing of sarcoma cells by proapoptotic Bcl-X(S): role of the BH3 domain and regulation by Bcl-X(L). Neoplasia 3 (2001) 437-445
66. Hossini A.M., Eberle J., Fecker L.F., Orfanos C.E., and Geilen C.C. Conditional expression of exogenous Bcl-X(S) triggers apoptosis in human melanoma cells in vitro and delays growth of melanoma xenografts. FEBS Lett. 553 (2003) 250-256
67. Clarke M.F., Apel I.J., Benedict M.A., Eipers P.G., Sumantran V., Gonzalez-Garcia M., et al. A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 11024-11028
68. Ealovega M.W., McGinnis P.K., Sumantran V.N., Clarke M.F., and Wicha M.S. bcl-xs gene therapy induces apoptosis of human mammary tumors in nude mice. Cancer Res. 56 (1996) 1965-1969
69. Sumantran V.N., Ealovega M.W., Nunez G., Clarke M.F., and Wicha M.S. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res. 55 (1995) 2507-2510
70. Ohi Y., Kim R., and Toge T. Overcoming of multidrug resistance by introducing the apoptosis gene, bcl-Xs, into MRP-overexpressing drug resistant cells. Int. J. Oncol. 16 (2000) 959-969
71. Taylor J.K., Zhang Q.Q., Wyatt J.R., and Dean N.M. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol. 17 (1999) 1097-1100
72. Shangary S., and Johnson D.E. Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 17 (2003) 1470-1481
73. Juin P., Geneste O., Raimbaud E., and Hickman J.A. Shooting at survivors: Bcl-2 family members as drug targets for cancer. Biochim. Biophys. Acta 1644 (2004) 251-260
74. O'Neill J., Manion M., Schwartz P., and Hockenbery D.M. Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy. Biochim. Biophys. Acta 1705 (2004) 43-51
75. Fischer U., and Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ. 12 Suppl. 1 (2005) 942-961